GENE ONLINE|News &
Opinion
Blog

Takeda Pharmaceutical
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
tRNA Startup Clinches $24 Million from ARCH, Takeda and 8VC to Fix Protein Mutations
2022-02-25
Takeda Taps Code Biotherapeutics to Develop Non-Viral Gene Therapies in $2 Billion Biobucks Deal
2022-02-23
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2022-01-14
Korro Bio Raises $116 Million for RNA Editing Program
2022-01-06
Takeda’s Livtencity Bags FDA Approval for the Treatment of Post-Transplant Infection
2021-11-24
Takeda Snags UK-Based Cell Therapy Collaborator to Boost Immuno-Oncology Portfolio
2021-10-27
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
Takeda Embarks On a Billion-Dollar Gene Therapy Deal with Selecta Biosciences
2021-10-08
Takeda Hits the Brakes on Narcolepsy Drug Trials
2021-10-07
Takeda’s Allogeneic Stem Cell Therapy Becomes First of Its Kind to Be Approved in Japan
2021-09-28
Takeda to Supply 150 Million Doses of Novavax COVID-19 Vaccine to Japan
2021-09-08
Takeda To Develop Rare Liver Disease Treatments with Genevant in $303M Pact
2021-08-24
1 2 3 4 5
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top